BIFIDOBACTERIUM ANIMALIS SSP. LACTIS GCL2505 REDUCES ABDOMINAL VISCERAL FAT, A KEY FACTOR ASSOCIATES WITH METABOLIC DISORDERS
Institute of Health Sciences, Ezaki Glico Co., Ltd., Japan
Gut microbiota currently has been recognized as an important factor for causes of overweight, obesity and excess accumulation of abdominal visceral fat, which is a known underlying component of metabolic syndrome (MS). Several studies indicated that gut bifidobacteria elicited beneficial effects on obesity and excess accumulation of fat mass, and also reported that the number of Bifidobacterium in feces was lower in overweight and obese subjects than in lean subjects. Bifidobacterium animalis ssp. lactis GCL2505 (B. lactis GCL2505) as a probiotics, which was previously shown to reach the gut, proliferates there and subsequently increases the total number of gut bifidobacteria. We previously showed that B. lactis GCL2505 proliferated in the gut and improve visceral fat accumulation in animal study. The aim of the present study was to investigate the impact of B. lactis GCL2505 on abdominal visceral fat storage in overweight and mildly obese Japanese adults.
A multicenter, randomized, double-blind, placebo-controlled intervention trial was performed for 12 weeks. Healthy Japanese subjects (N=137) with body mass index ranging 23 - 30 kg/m2 consumed either fermented milk containing 8×1010 CFU of B. lactis GCL2505 (GCL2505 group) or placebo (placebo group) every day. Abdominal visceral fat area (VFA) and subcutaneous fat area (SFA) were measured by computed tomography. Furthermore, the number of fecal bifidobacteria was measured.
Compared with the placebo group, the VFA in the GCL2505 group was significantly reduced from baseline at 8 and 12 weeks (-6.8 cm2 and -5.1 cm2, respectively). However there was no reduction in SFA. The total number of fecal bifidobacteria was significantly increased in the GCL2505 group, compared with in the placebo group during the treatment period (p < 0.001). There were no significant differences in nutrient intake (dietary energy, protein, carbohydrate, and fat) and steps walked during treatment period. No adverse events were also observed throughout this study in any subjects either.
In the present study, we revealed that the intake of B. lactis GCL2505 led to increase in the gut bifidobacteria and reduce visceral fat accumulation in overweight and mildly obese adults. Several studies showed that a higher abundance of gut bifidobacteria was associated with suppressed excess accumulation of fat mass. These results suggest that increasing gut bifidobacteria by ingesting B. lactis GCL2505 might play an important role in reducing abdominal visceral fat. Therefore, our findings in the present clinical study suggest that a specific strain of B. lactis GCL2505 may be useful for the reduction of abdominal visceral fat, and improve metabolic disorders in overweight or mildly obese individuals.
Keywords: Randomized trial, Visceral fat, Bifidobacterium, Probiotics, Overweight
Takahashi S. (2016). Bifidobacterium animalis ssp. lactis GCL 2505 reduces abdominal visceral fat, a key factor associates with metabolic disorders.
Conference Proceedings of IPC2016. Paper presented at the International Scientific Conference on Probiotics and Prebiotics, Budapest (p. 119.). IPC2016